The U.S. Food and Drug Administration (FDA) has announced its approval of a groundbreaking solution to address postpartum depression (PPD). Zurzuvae is the first oral medication for PPD, offering an alternative to the previously limited intravenous injection treatment. ‍

Read the full statement made by the FDA to gain a comprehensive understanding of the role Zurzuvae plays in addressing this issue, its demonstrated efficacy, potential side effects, and its broader implications for maternal and child well-being.